Possible roles of IL-12-family cytokines in rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 9, Issue 4, 2013, Pages 252-256

  Pope, Richard M ^a   Shahrara, Shiva ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APILIMOD; BRODALUMAB; CATHEPSIN K; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 27; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 6; IXEKIZUMAB; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PEPTIDE VACCINE; PLACEBO; RECOMBINANT GAMMA INTERFERON; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; USTEKINUMAB;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; BONE EROSION; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOPATHOGENESIS; LEUKOCYTE MIGRATION; LYMPHOCYTE DIFFERENTIATION; MONOTHERAPY; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; COHORT STUDIES; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; MICE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84876406357     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.170     Document Type: Review

References (53)

1. Collison, L. W. & Vignali, D. A. Interleukin-35: odd one out or part of the family? Immunol. Rev. 226, 248-262 (2008).
2. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
3. Collison, L. W. et al. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13, 290-299 (2012).
4. Hunter, C. A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531 (2005).
5. Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852 (2007).
6. Nakanishi, K., Yoshimoto, T., Tsutsui, H. & Okamura, H. Interleukin-18 is a unique cytokine that stimulates both TH1 and TH2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12, 53-72 (2001).
7. Petrovic-Rackov, L. & Pejnovic, N. Clinical significance of IL-18, IL-15, IL-12 and TNFα measurement in rheumatoid arthritis. Clin. Rheumatol. 25, 448-452 (2006).
8. Yin, Z. et al. The elevated ratio of interferon γ-/interleukin-4- positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor β. Rheumatology (Oxford) 38, 1058-1067 (1999).
9. Leipe, J. et al. Role of TH17 cells in human autoimmune arthritis. Arthritis Rheum. 62, 2876-2885 (2010).
10. Shahrara, S., Huang, Q., Mandelin, A. M. 2nd & Pope, R. M. TH17 cells in rheumatoid arthritis. Arthritis Res. Ther. 10, R93 (2008).
11. Holmdahl, R. et al. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS 97, 575-584 (1989).
12. Germann, T. et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl Acad. Sci. USA 92, 4823-4827 (1995).
13. Joosten, L. A., Lubberts, E., Helsen, M. M. & van den Berg, W. B. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J. Immunol. 159, 4094-4102 (1997).
14. Paunovic, V., Carroll, H. P., Vandenbroeck, K. & Gadina, M. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12,-17,-23 and-27 in autoimmunity. Rheumatology (Oxford) 47, 771-776 (2008).
15. Sarkar, S. & Fox, D. A. Targeting IL-17 and TH17 cells in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 36, 345-366 (2010).
16. Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006).
17. Paradowska-Gorycka, A., Grzybowska-Kowalczyk, A., Wojtecka-Lukasik, E. & Maslinski, S. IL-23 in the pathogenesis of rheumatoid arthritis. Scand. J. Immunol. 71, 134-145 (2010).
18. Murphy, C. A. et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003).
19. Brentano, F. et al. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann. Rheum. Dis. 68, 143-150 (2009).
20. Stamp, L. K., Easson, A., Pettersson, L., Highton, J. & Hessian, P. A. Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J. Rheumatol. 36, 2403-2408 (2009).
21. Langrish, C. L. et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96-105 (2004).
22. Liu, F. L. et al. Interleukin (IL)-23 p19 expression induced by IL-1β in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-κB and AP-1 dependent pathway. Rheumatology (Oxford) 46, 1266-1273 (2007).
23. Kim, H. R. et al. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand. J. Rheumatol. 36, 259-264 (2007).
24. Chen, L., Wei, X. Q., Evans, B., Jiang, W. & Aeschlimann, D. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-κB (RANK) expression in myeloid precursor cells. Eur. J. Immunol. 38, 2845-2854 (2008).
25. Li, X. et al. IL-23 induces receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-κB signal pathways. Immunol. Lett. 127, 100-107 (2010).
26. Sato, K. et al. TH17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
27. Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345-1352 (1999).
28. Nakae, S., Nambu, A., Sudo, K. & Iwakura, Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171, 6173-6177 (2003).
29. Ratsimandresy, R. A. et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine 29, 9329-9336 (2011).
30. Wiekowski, M. T. et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166, 7563-7570 (2001).
31. Niedbala, W. et al. Interleukin 27 attenuates collagen-induced arthritis. Ann. Rheum. Dis. 67, 1474-1479 (2008).
32. Pflanz, S. et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16, 779-790 (2002).
33. Diveu, C., McGeachy, M. J. & Cua, D. J. Cytokines that regulate autoimmunity. Curr. Opin. Immunol. 20, 663-668 (2008).
34. Cao, Y., Doodes, P. D., Glant, T. T. & Finnegan, A. IL-27 induces a TH1 immune response and susceptibility to experimental arthritis. J. Immunol. 180, 922-930 (2008).
35. Batten, M. et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7, 929-936 (2006).
36. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937-945 (2006).
37. Stumhofer, J. S. et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8, 1363-1371 (2007).
38. Wojno, E. D. & Hunter, C. A. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 33, 91-97 (2012).
39. Iyer, S. S., Ghaffari, A. A. & Cheng, G. Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J. Immunol. 185, 6599-6607 (2010).
40. Kalliolias, G. D., Gordon, R. A. & Ivashkiv, L. B. Suppression of TNFα and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J. Immunol. 185, 7047-7056 (2010).
41. Kalliolias, G. D., Zhao, B., Triantafyllopoulou, A., Park-Min, K. H. & Ivashkiv, L. B. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 62, 402-413 (2010).
42. Pickens, S. R. et al. Local expression of IL-27 ameliorates collagen-induced arthritis. Arthritis Rheum. 63, 2289-2298 (2011).
43. Collison, L. W. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569 (2007).
44. Collison, L. W. et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093-1101 (2010).
45. Niedbala, W. et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of TH17 cells. Eur. J. Immunol. 37, 3021-3029 (2007).
46. Kochetkova, I., Golden, S., Holderness, K., Callis, G. & Pascual, D. W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol. 184, 7144-7153 (2010).
47. Veys, E. M. et al. Interferon γ in rheumatoid arthritis-a double blind study comparing human recombinant interferon γ with placebo. J. Rheumatol. 15, 570-574 (1988).
48. Seitz, M., Franke, M. & Kirchner, H. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon γ. Ann. Rheum. Dis. 47, 642-644 (1988).
49. Krausz, S. et al. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 26, 1750-1755 (2012).
50. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
51. Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633-640 (2009).
52. Genovese, M. C. et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929-939 (2010).
53. Papp, K. A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189 (2012).